MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)
Key facts
- Who runs it
- Austin V Stone
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 30 people, planned
- Started
- 1 Feb 2021
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Montelukast
- Placebo
- Record updated
- 10 June 2026
Who can take part
- Age
- 25 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Undergoing primary ACL reconstruction
- Age between 25-50
- Concomitant meniscus injury
Who cannot take part
- Found to not have a meniscus tear at the time of surgery
- Undergoing revision procedures
- Multiple ligament injuries requiring multiple ligament reconstruction/repair
- Depressive symptoms and/or those who endorse suicidal ideation at the time of enrollment (PHQ-9 score >= 15)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 50 years old?
Where in United States
- UK Healthcare at TurflandLexington, United StatesContact: Austin Stone, MD, PhDTaking people
About the trial
What the trial wants to find out
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
The 2 groups in the trial
- MontelukastTreatment being tested
Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
- PlaceboPlacebo, for comparison
Patients will receive an oral placebo daily for 6 months after surgery.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT04572256, who can take part
- Record updated
- 10 June 2026